| 李娟 兰为群 韩萍 李晓端 丁永英.瑞舒伐他汀对高胆固醇血症患者的降脂疗效及对血管内皮舒张功能
的影响[J].,2016,16(17):3370-3372 |
| 瑞舒伐他汀对高胆固醇血症患者的降脂疗效及对血管内皮舒张功能
的影响 |
| Effect of Lowering Blood Lipid of Rosuvastatin on Patients withHypercholesterolemia and Improving Diastolic Function of VascularEndothelium |
| |
| DOI： |
| 中文关键词: 瑞舒伐他汀 高胆固醇血症 降脂 血管内皮依赖性舒张功能 |
| 英文关键词: Rosuvastatin Hypercholesterolemia Blood Lipid-lowering Flow-mediated dilation(FMD) |
| 基金项目: |
|
| 摘要点击次数: 761 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨瑞舒伐他汀对高胆固醇血症患者的降脂疗效及对血管内皮舒张功能(FMD)的影响。方法：选择我院92 例高胆固
醇血症患者作为实验组并给予瑞舒伐他汀治疗，另选择同期来我院参加健康体检的健康志愿者42 例作为对照组，检测治疗前
(T0)，以及治疗1 个月(T1)、2 个月后(T2)的血脂水平及肱动脉FMD 和非依赖性血管内皮舒张功能(NMD)，并对其治疗的不良反
应情况进行统计分析。结果：治疗前，实验组患者血浆中TC、TG 和LDL-C 水平明显高于对照组，而HDL-C 水平显著低于对照
组，且差异均具有统计学意义（P<0.05）。相对于T0，实验组患者T1 和T2 血浆中TC、TG 和LDL-C水平明显下降，而HDL-C 水平
显著升高，且差异均具有统计学意义（P<0.05）。患者T2 时血浆中TC和LDL-C 水平明显低于T1 的水平（P<0.05），而TG和
HDL-C 水平与T1 之间的差异无统计学意义（P>0.05）；治疗前，实验组患者的FMD 值明显低于对照组的健康志愿者(P<0.05)。经
过瑞舒伐他汀干预2 个月后，实验组患者T2 时FMD 值明显高于T0 (P<0.05)，而T2 的NMD 与T0 之间的差异无统计学意义
(P>0.05)；治疗期间并未出现严重的不良反应。结论：瑞舒伐他汀对老年高胆固醇血症患者降脂效果显著，且有改善FMD 的作用。 |
| 英文摘要: |
| Objective:To explore efficacy of lowering blood lipid of rosuvastatin on patients with hypercholesterolemia and its
improving flow-mediated dilation(FMD).Methods:A total of 92 elderly patients with hypercholesterolemia were chosen as experimental
group, who were treated with rosuvastatin; in addition, 42 healthy volunteers, as control group. The levels of lipid and FMD and non-mediated
dilation(NMD) of brachial artery were detected before treatment(T0), and 1 month after treatment(T1), 2 months(T2); meanwhile,
the adverse reactions of treatment situation were analyzed.Results:Before treatment, the levels of TC, TG, LDL-C in the serum of patients
in the experimental group were obviously higher than those in the control group, while the level of HDL-C was significantly lower
than that in the control group, the differences were statistically significant (P<0.05). Compared with T0, levels of TC, TG, LDL-C of patients
in the experimental group at T1 and T2 were declined obviously, while the HDL-C level increased, the differences were statistically
significant (P<0.05). The levels of TC and LDL-C of the patients at T2 were significantly lower than at T1 (P<0.05), but the differences
of the levels of TG and HDL-c between T1 and T2 had no statistical significance (P>0.05). Before treatment, the value of FMD in the experimental
group was lower than that in the control group significantly(P<0.05). After 2 months of rosuvastatin intervention, the value of
FMD of the patients in the experimental group at T2 was significantly better than at T0 (P<0.05), while differences of NMD between T2
and T0 had no statistical significance (P>0.05). There were no serious adverse reactions during the treatment.Conclusion:Rosuvastatin
has significant effect of lowering blood lipid in the treatment of patients with hyperlipidemia, and can improve the FMD. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
